Elimination of serum proteins and potential virus contaminants during hepatitis B vaccine preparation

Adamowicz, P; Chabanier, G; Hyafil, François; Lucas, Georges; Prunet, P; Reculard, P; Vinas, Roger

doi:10.1016/0264-410x(84)90087-2

Cited by 14 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first generation prophylactic hepatitis B vaccine was made from the pooled plasma of hepatitis carriers. But published information concerning the amount of allogeneic material in the final preparation is in short supply except admission that a vaccine had traces of serum proteins [75][76][77][78]. Thus we cannot determine whether this vaccine was bona fide alloimmune vaccine although no one seems to have purposefully investigated the contribution of contaminant alloantigens.…”

Section: Alloimmunizationmentioning

confidence: 95%

Clinical Experience with Therapeutic Vaccines Designed for Patients with Hepatitis

Batdelger¹,

Dandii²,

Yagaanbuyant³

et al. 2009

CPD

View full text Add to dashboard Cite

Franciscan missionary Giovanni Di Plano Carpini traveled in 1245 to a country named Yeke Tartar, to visit a certain man called Genghis Khan. His journey's report narrated peculiar dietary habits of the locals: "they eat anything, even lice". Little that Carpini knew, he had actually documented the earliest known to us record of oral vaccination against blood-borne infections - an approach that is still used occasionally in the present-day Mongolia for therapy of hepatitis. Currently, efforts aimed at developing therapeutic hepatitis vaccines have switched to more palatable path, but we may still benefit from the insight of medieval Mongols. This review provides an update on development of hepatitis B and C vaccines as related to immunotherapy of hepatitis. Immune therapy is a fast-moving field but the results so far failed to pitch woo. Current trends in research on therapeutic vaccine candidates and liver immunology are discussed. We subscribe to the idea that viral hepatitis is essentially an autoimmune disease generating immune-mediated liver damage. Therapeutic vaccines need to be designed in such a way that self-destructive immunity of the host is targeted not the virus, which is not cytopathic.

show abstract

Section: Alloimmunizationmentioning

confidence: 95%

Clinical Experience with Therapeutic Vaccines Designed for Patients with Hepatitis

Batdelger¹,

Dandii²,

Yagaanbuyant³

et al. 2009

CPD

View full text Add to dashboard Cite

show abstract

Monoliths in Bioprocessing

Podgornik

Barut

Peterka

et al. 2012

Biopharmaceutical Production Technology

View full text Add to dashboard Cite

Controlled fed‐batch fermentation of recombinant Saccharomyces cerevisiae to produce hepatitis B surface antigen

Hsieh

Shih

Kung

et al. 1988

Biotech & Bioengineering

View full text Add to dashboard Cite

We have performed controlled fed-batch fermentation experiments to compare the production level of hepatitis B surface antigen (HBsAg) by recombinant yeast Saccharomyces cerevisiae strains (YNN27/pYBH-1, YNN27/ p2micro-S11, YNN27/pDCB-S2) containing plasmid vector with alcohol dehydrogenase (ADH1), acid phosphatase (PHO5), and glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter, respectively. Yeast cell concentrations of 15-35 g dry cell weight/L were obtained. By limiting phosphorous concentration, HBsAg expression level for the YNN27/p2micro-S11 strain with inducible PHO5 promoter reached 0.2-0.3 mg/L. By controlling nutrient addition rate and dissolved oxygen concentration, HBsAg concentrations of 3-10 mg/L were achieved in 60-70 h fermentation using the YNN27/pDCB-S2 strain with the constitutive GPD promoter.

show abstract

Elimination of serum proteins and potential virus contaminants during hepatitis B vaccine preparation

Cited by 14 publications

References 14 publications

Clinical Experience with Therapeutic Vaccines Designed for Patients with Hepatitis

Clinical Experience with Therapeutic Vaccines Designed for Patients with Hepatitis

Monoliths in Bioprocessing

Controlled fed‐batch fermentation of recombinant Saccharomyces cerevisiae to produce hepatitis B surface antigen

Contact Info

Product

Resources

About